24 July 2024
Biomanufacturing workflow NK cells revolutionizes immunotherapy

All images are AI generated

Spread the love

Revolutionizing Cancer Treatments with Biomanufacturing Workflow for NK Cells

Natural killer (NK) cells and extracellular vesicles (EVs) hold immense potential in revolutionizing cancer treatments. A recent study conducted by researchers at the University of Ottawa Faculty of Medicine has proposed a large-scale biomanufacturing workflow aimed at producing NK cells and EVs. This innovative approach could significantly impact how Canada generates immunotherapeutic materials, paving the way for novel cancer treatments in the future.

The proof-of-concept study detailed in the Journal of Extracellular Vesicles focuses on utilizing a hollow-fiber bioreactor to facilitate the production of these crucial immunotherapeutic materials. This bioreactor, equipped with thousands of semipermeable fibers in a small cartridge, enables a continuous flow of cell-derived immunotherapeutics without compromising their quality and anti-cancer characteristics. Dr. Jessie Lavoie, one of the senior authors of the study, emphasizes the importance of efficient and cost-effective solutions in generating large quantities of high-quality materials for pre-clinical and clinical investigations.

Enhancing Feasibility and Cost-Effectiveness of Biomanufacturing Production

According to Dr. Lavoie, the accessibility of low-cost and continuous closed systems is essential for meeting the demands of cell and EV therapies. The development of such a biomanufacturing workflow holds the potential to streamline the production process and make it more cost-effective. This could be a game-changer for drug developers in Canada, offering new avenues for developing and advancing innovative therapies.

Related Video

Published on: March 2, 2023 Description: A webinar is conducted on Biomanufacturing 4.0 by BIS Research. Cell and gene therapy are promising fields of biomedical ...
Biomanufacturing 4.0 – A New Era in Cell and Gene Therapy Development
Play

The study highlights the significance of establishing large-scale biomanufacturing systems that can produce NK cells and EVs in quantities far exceeding those achievable through conventional methods. By employing hollow-fiber bioreactors, the researchers aim to address the need for affordable and scalable systems that can cater to the requirements of laboratories, including academic centers driving the development of cell therapy products in Canada.

Implications for Cancer Immunotherapy Research

The biomanufacturing workflow proposed by the uOttawa Faculty of Medicine researchers opens up new possibilities in the field of cancer immunotherapy research. Dr. Lisheng Wang, another senior author of the study, highlights the potential impact of this approach in offering novel options for drug developers seeking cost-effective means to explore and advance innovative therapies. The utilization of hollow-fiber bioreactors presents a promising avenue for scaling up the production of EVs, thereby expanding the availability of these critical materials for research and clinical applications.

The study published in the Journal of Extracellular Vesicles underscores the commitment of the uOttawa Faculty of Medicine to pushing the boundaries of EVs and immunotherapy research. With a focus on innovation and discovery, the Faculty’s research community continues to make significant strides in advancing the understanding and application of NK cells and EVs in cancer treatment.

Future Prospects and Collaborative Efforts in Biomanufacturing

Looking ahead, the development of a large-scale biomanufacturing workflow for NK cells and EVs holds immense promise for the future of cancer therapeutics. By enhancing the feasibility and cost-effectiveness of producing these immunotherapeutic materials, researchers aim to catalyze the development of novel treatment modalities that could potentially transform the landscape of cancer care.

The collaborative efforts of academia, small biotechnology companies, and drug developers in Canada are crucial in driving forward the implementation of efficient biomanufacturing solutions. As the research community continues to explore innovative approaches to bioprocessing and cell therapy production, the integration of advanced technologies such as hollow-fiber bioreactors offers a pathway towards scalable and sustainable manufacturing of NK cells and EVs for cancer immunotherapy.

The proposed biomanufacturing workflow represents a significant step towards harnessing the potential of NK cells and EVs in advancing cancer treatments. By leveraging innovative technologies and collaborative partnerships, researchers are poised to make substantial contributions to the field of cancer immunotherapy, ultimately benefiting patients worldwide with more effective and accessible treatment options.

Links to additional Resources:

1. www.sciencedirect.com/science/article/abs/pii/S1096717623000602?dgcid=coauthor 2. www.nature.com/articles/s41551-023-01064-6 3. www.ncbi.nlm.nih.gov/pmc/articles/PMC9186939/

Related Wikipedia Articles

Topics: Natural killer cells, Extracellular vesicles, Bioreactor

Natural killer cell
Natural killer cells, also known as NK cells or large granular lymphocytes (LGL), are a type of cytotoxic lymphocyte critical to the innate immune system. They belong to the rapidly expanding family of known innate lymphoid cells (ILC) and represent 5–20% of all circulating lymphocytes in humans. The role of...
Read more: Natural killer cell

Extracellular vesicle
Extracellular vesicles (EVs) are lipid bilayer-delimited particles that are naturally released from almost all types of cells but, unlike a cell, cannot replicate. EVs range in diameter from near the size of the smallest physically possible unilamellar liposome (around 20-30 nanometers) to as large as 10 microns or more, although...
Read more: Extracellular vesicle

Bioreactor
A bioreactor refers to any manufactured device or system that supports a biologically active environment. In one case, a bioreactor is a vessel in which a chemical process is carried out which involves organisms or biochemically active substances derived from such organisms. This process can either be aerobic or anaerobic....
Read more: Bioreactor

Leave a Reply

Your email address will not be published. Required fields are marked *